对于有潜在不稳定代谢物的物质，应确认制剂后基质中分析物稳定性。
For compounds with potentially labile metabolites, the stability of analyte in matrix from dosed subjects (or species) should be confirmed.
目的：评价基质金属蛋白酶抑制剂临床应用的疗效与安全性。
OBJECTIVE: to evaluate the efficiency and safety of matrix metallo-proteinase inhibitor in clinical application.
结论：乳剂型软膏基质制成的淫羊藿苷制剂释药速度最快。
Conclusion: the drug releasing rate of Icariin ointment made of emulsion ointment base is the fastest.
应用推荐